These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 9815930)
1. Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples. Geoffroy F; Dahut W; Takimoto CH; Grem JL Clin Cancer Res; 1995 Nov; 1(11):1345-51. PubMed ID: 9815930 [TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982 [TBL] [Abstract][Full Text] [Related]
3. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. de Souza PL; Cooper MR; Imondi AR; Myers CE Clin Cancer Res; 1997 Feb; 3(2):287-94. PubMed ID: 9815685 [TBL] [Abstract][Full Text] [Related]
4. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Ross DD; Chen SR; Cuddy DP Cancer Res; 1990 May; 50(9):2658-66. PubMed ID: 2328491 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological determinants of 9-aminocamptothecin cytotoxicity. Li ML; Horn L; Firby PS; Moore MJ Clin Cancer Res; 2001 Jan; 7(1):168-74. PubMed ID: 11205905 [TBL] [Abstract][Full Text] [Related]
6. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Leguizamo J; Quinn M; Takimoto CH; Liang MD; Ismail AS; Pang J; Dahut W; Grem JL Cancer Chemother Pharmacol; 2003 Oct; 52(4):333-8. PubMed ID: 12819941 [TBL] [Abstract][Full Text] [Related]
7. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Sparreboom A; de Jonge MJ; Punt CJ; Nooter K; Loos WJ; Porro MG; Verweij J Clin Cancer Res; 1998 Aug; 4(8):1915-9. PubMed ID: 9717819 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Minami H; Lad TE; Nicholas MK; Vokes EE; Ratain MJ Clin Cancer Res; 1999 Jun; 5(6):1325-30. PubMed ID: 10389915 [TBL] [Abstract][Full Text] [Related]
10. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Geoffroy FJ; Allegra CJ; Sinha B; Grem JL Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. Takimoto CH; Dahut W; Marino MT; Nakashima H; Liang MD; Harold N; Lieberman R; Arbuck SG; Band RA; Chen AP; Hamilton JM; Cantilena LR; Allegra CJ; Grem JL J Clin Oncol; 1997 Apr; 15(4):1492-501. PubMed ID: 9193345 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917 [TBL] [Abstract][Full Text] [Related]
13. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells. Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189 [TBL] [Abstract][Full Text] [Related]
14. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Kirichenko AV; Rich TA; Newman RA; Travis EL Cancer Res; 1997 May; 57(10):1929-33. PubMed ID: 9157987 [TBL] [Abstract][Full Text] [Related]
15. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Pitot HC; Knost JA; Mahoney MR; Kugler J; Krook JE; Hatfield AK; Sargent DJ; Goldberg RM Cancer; 2000 Oct; 89(8):1699-705. PubMed ID: 11042563 [TBL] [Abstract][Full Text] [Related]
16. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Kirstein MN; Houghton PJ; Cheshire PJ; Richmond LB; Smith AK; Hanna SK; Stewart CF Clin Cancer Res; 2001 Feb; 7(2):358-66. PubMed ID: 11234891 [TBL] [Abstract][Full Text] [Related]
17. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726 [TBL] [Abstract][Full Text] [Related]
19. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor. Myers CE; Young RC; Chabner BA Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826 [TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Xiong HQ; Tran HT; Madden TL; Newman RA; Abbruzzese JL Clin Cancer Res; 2003 Jun; 9(6):2066-71. PubMed ID: 12796369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]